Introduction u n c o r r e c t e d p r o o f
The identification and mapping of sentinel lymph nodes (SLN) for biopsy or imaging are commonly used for staging of many cancers especially breast cancer. Therefore, SLN has an importance as being the first node draining the primary tumor to which a malignancy is likely to metastasize. Various dyes have been used for SLN identification such as isosulphane blue and methylene blue (MB). MB is a cheap and easily accessible dye which is approved by FDA. Additionally, its side effects are less serious than isosulphane blue. 1, 2 The limiting factor of MB is its poor penetration through the cell membranes and some allergic reactions. Radiopharmaceuticals have been used as an alternative or in addition to dyes for external imaging and/or radiation detector monitoring for the SLN detection and mapping before surgery. Intraoperative use of gamma probe detectors permits confirming of external sampling procedures by directly counting the various lymph nodes discovered through a small incision. By the use of these methods, various advantages can be achieved; 1. significant time reduction of surgical procedure, 2. a significant increase in the accuracy of SLN identification, and 3. a significant decrease in the morbidity due to the staging procedure. 3 Although some researchers reported that sentinel lymph node (SLN) biopsy can be performed by using only radioactive colloid injection due to preventing some allergic reactions caused by the blue dye such as MB 4 , it is adviced to use dye together with the radioisotope for the accurate detection of SLN at early stage breast cancer patients especially. This combined technique provides detection of SLN about 99%. Recently, MB was also confirmed to detect the breast tumors with Near-infrared (NIR) fluorescence imaging injection after i.v. administration. 2 NIR imaging is a relatively new field for the investigation of both preclinical and clinical applications in cancer imaging due to having a high spatial resolution, portability and real-time display. NIR light range (wavelength: 650-900 nm) provides tissue penetration and less autofluorescence from surrounding tissues. 5 Currently, Photodynamic therapy (PDT) has been investigated as an alternative treatment option for a variety of cancers.
6-8 Its mechanism is based on the photooxidation of biological matters. The uptake of a photosensitizer followed by illumination with light having an appropriate wavelength that is able to excite photosensitizer and induce photochemical reactions that generate reactive oxygen species (such as singlet oxygen ( 1 O2), and radicals) inducing cell death.
9, 10 PDT has been used as an experimental treatment approach for different cancer types in many countries 11, 12 and it is generally approved as an effective therapy approach in some small and localized tumors. 13 Reduced long-term morbidity is the most important advantage of PDT. 9, 14 Encapsulation or modification of active pharmaceutical ingredients and/or contrast/radiocontrast agents in nanosystems is desirable due to the enhancement of bioavailability and organ/tissue accumulation by specific targeting, and decrease side effects and dose. Liposomes kept significant attention for both diagnostic imaging 15 and therapy 16 due to the suitable properties such as ability to encapsulate drugs having different physicochemical properties and modify with target specific ligands. [17] [18] [19] By the effect of reducing particle size to nanometer ranges, surface modification with proper polymers such as PEG steric stabilization can be achieved and rapid removal of liposomes from blood-circulation by opsonization with reticulo-endothelial system (RES) such as plasma proteins and macrophages can be prevented. 20, 21 Therefore, enhanced blood-circulation time, bioavailability and especially in the case of diseases related with damaged vessel integrity to enhance drug delivery accumulation and targeting in the desired disease area by enhanced permeability and retention (EPR) effect such as tumor can be achieved finally. The use of liposomes for the delivery of MB has potential advantages due to their properties. Encapsulation of MB in liposomal formulations can reduce some undesired side effects of MB such as allergic reactions, the volume of distribution by increasing accumulation at the desired site and the dose significantly. The poor penetration of MB through the cell membranes and its slight side effects such as allergic reactions can be decreased by encapsulating in liposomal systems. Recently, near-infrared (NIR) imaging can be used with PDT for theranostic approach by using proper photosensitizer dyes. MB, as a cheap and safe dye, has both NIR fluorescence (excitation: 668 nm, emission: 688 nm) and photosensitizer properties. To evaluate sentinel lymph node detection, MB, isosulphane blue, radioisotopes and nanocarriers have been used as single or in combination in some previous studies for lymphoscintigraphy and SLN biopsy as a promising approach. 3, [22] [23] [24] However, the poor penetration of MB through the cell membranes is the limiting factor. Its decreased cellular uptake can be prevented by encapsulating MB in drug delivery systems such as liposomes. Combining radionuclide and photosensitizer dye (MB) in one injection can provide both lymphoscintigraphy or lymphatic mapping by nuclear imaging and NIR imaging and also PDT by application of a light having a proper light which can help SLN surgery. In this study, it was aimed to formulate MB encapsulated, Tc-99m radiolabeled, PEGylated liposomes to design a multifunctional theranostic nanocarrier for NIR imaging, detection by gamma probe of SLN and PDT which can be combined with surgery with a single vesicular system. The characterization of liposomes was performed by measuring particle size, zeta potential, phospholipid content, radiolabeling efficiency and encapsulation efficiency. In vitro release profile of MB was determined. In vitro stability of liposomes was also evaluated for six months which were stored at room temperature (25 ͦ C) and 4 ͦ C.
Methods Materials u n c o r r e c t e d p r o o f
Lipoid S PC (Phosphatidylcholine from Soybean (98%)) and Dipalmitoylphosphatidylcholine (DPPC) were kind gifts of Lipoid GmbH (Ludwigshafen, Germany) and Phospholipon GmbH (Cologne, Germany), respectively. Cholesterol (Chol) was obtained from (Sigma-Aldrich, St. Louis, Missouri, USA). 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (PEG2000-DSPE) and 1,2-Dioleoiyl-sn-glicero-3-phosphoethanolamine (DOPE) were obtained from Avanti Polar Lipids, Inc., Alabaster, Alabama, USA. Diethylenetriaminepentaacetic acid anhydride (DTPA) and Methylene blue were obtained from Sigma-Aldrich. Dimethyl sulfoxide (DMSO) was obtained from Merck, Darmstadt, Germany. Synthesis of DTPA-PE DTPA-PE, is used for Tc-99m radiolabeling. For the synthesis, 0.1 mM of DOPE in 4 mL of chloroform was supplemented with 30 μL of triethylamine. This solution was added dropwise to another solution of 1 mM of DTPA anhydride in 20 mL of DMSO. It was then incubated for 3 hours at room temperature (25 ͦ C) under argon gas. Afterwards, the mixed solution was dialyzed against 6 L of water at 4°C for 48 hours. Purified DTPA-PE was freeze-dried and stored frozen at −80°C. 25, 26 Preparation of MB Encapsulated, PEGylated, DTPA-PE Containing Liposomes MB encapsulated, nanosized liposomes were formulated by film hydration method (Bangham et al. 1965 ). Lipoid S PC:PEG2000-PE:Chol:DTPA-PE (60:0,9:39:0,1% molar ratio) were used. For this purpose, Lipoid S PC, PEG2000-PE, cholesterol and DTPA-PE were dissolved in chloroform at 35 ͦ C. Chloroform was then evaporated and the dry lipid film was hydrated with 0.5 mM MB solution (5 mL) in HEPES (1 M, pH 7.4) buffer at 35 ͦ C. Multilamellar vesicles were extruded 2 times through polycarbonate membranes having 0.6 µm, 0.4 µm and 0.2 µm pore sizes, respectively. Afterwards, liposomes were dialyzed through a regenerated cellulose membrane (3,500 Da cut-off size) for 12 hours to remove unencapsulated MB. For the prepartion of DPPC as phospholipid containing liposomes DPPC:PEG2000-PE:Chol:DTPA-PE (60:0,9:39:0,1% molar ratio) were used for mixture. The same procedure was also used for the preparation of MB encapsulated DPPC:PEG2000-PE:Chol:DTPA-PE liposomes, the only difference is that the hydration procedure was performed at 60 ͦ C.
Characterization of MB Encapsulated, PEGylated, DTPA-PE Containing Liposomes
The characterization of MB encapsulated, DTPA-PE containing, PEGylated nanosized Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposome formulations was determined by measuring mean particle size, zata potential, phosphate content and encapsulation efficiency (EE%).
Mean Particle Size and Zeta Potential Mean particle size and polydispersity index (PDI) and zeta potential of liposome formulations were determined using the Nano-ZS (Malvern Instruments, Malvern, UK) by dynamic light scattering method.
Encapsulation Efficiency (%) After the removal of unencapsulated MB by dialysis, liposome vesicles were lysed by ethanol. Encapsulated MB amount was determined spectrophotometrically at 660 nm. Encapsulation efficiency (%) was calculated with the help of standart line and line equation obtained previously. The percentage of entrapped drug was calculated by applying Equation 1: Entrappment Efficiency (%)= ( × 100)/( )………………………………………Eq. (1) where is the amount of entrapped drug and is the initial amount of drug. -Liposomal Phospholipid Amount Phosphate content of MB encapsulated, PEGylated, DTPA-PE containing liposome formulations was obtained by uing modified Rouser method (Rouser et al. 1970 ). This method depends on the determination of phosphorus content after perchloric acid destruction of liposomes at 797 nm using an ultraviolet spectrophotometer (Schimadzu UV-1280, Germany). Physical Stability of Liposomes Any alterations in mean particle size, zeta potential and MB leakage of MB containing Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were measured to evaluate in vitro physical stability of liposomes. For this purpose, liposomes were kept at two different temperatures (4°C and 25°C) for 6 months and the alterations of these parameters were determined at fixed time intervals (0, 3, 5, 7, 14, 21, 30, 60, 90, 120, 150, 180 days) for 6 months.
In Vitro Release Studies
In vitro release profile of MB was assessed by the dialysis method. 27 For this purpose, 1 mL of the liposomes were put in dialysis bags (MW cut-off: 2,000) in 10 mL of HEPES (1 M, pH 7.4) buffer, and agitated in a shaking water bath (SWB 5050, Labnet International, Canada) at a rate of 100 oscillations per minute which was incubated at 37°C. 1 mL of the dialysate was removed for the measurement of MB concentrations and 1 mL of HEPES (1 M, pH 7.4) buffer was added at specific time points. Release of MB in HEPES (1 M, pH 7.4) buffer was determined spectrophotometrically (Shimadzu, UV-1280, Duisburg). Radiolabeling of MB Encapsulated, PEGylated, DTPA-PE Containing Liposomes MB encapsulated, DTPA-PE containing, Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were labeled with Tc-99m by tin-reduction method. Briefly, 0.5 mL of u n c o r r e c t e d p r o o f SnCl2.2H2O (1 mg.mL -1 ) and 1.5 mCi of Tc-99m were incubated with liposomes for 30 minutes by shaking to allow transchelation. 28, 29 After incubation, liposomes were dialyzed against HEPES (1 M, pH 7.4) buffer for 5 hours at 4°C to remove unchelated Tc-99m by cellulose ester dialysis membrane (3,500-Da cut-off size). After removal of free Tc-99m, the radioactivity of liposomes was measured by a gamma counter.
Statistical Analysis
All data were given as mean±standard deviation. To evaluate the statistical significance of differences among the results, statistical analysis were performed. Depending on the numbers of data which are less than 30, nonparametric test methods were used for data evaluation. Depending on the group number, Mann-Whitney U test and Kruskal Wallis was used for the comparison of two groups and three or more groups, respectively. The significance level was set at p ≤ 0.05.
Results and Discussion
Tc-99m labeled, MB encapsulated liposomes were formulated for the purpose of SLN detection by gamma probe, NIR imaging and also PDT of SLN to perform better detection, mapping and also, treatment option helping surgery. MB encapsulated, Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were characterized. Mean particle size, PDI, EE%, and phospholipid amount of MB encapsulated, PEGylated, DTPA-PE containing liposomes are given in Table 1 . Mean particle sizes of all liposomes were observed to be approximately 100 nm. DPPC containing liposome dispersions have smaller particle size than Lipoid S PC containing ones (p > 0.05). MB encapsulation amount of DPPC containing liposomes was found to be higher than Lipoid S PC liposomes (P > 0.05). Phosphate content of liposomes found high about 85-90%. DPPC containing liposomes had higher phosphate content than Lipoid S PC containing ones (P > 0.05). Alterations in mean particle size, zeta potential and MB encapsulation efficiency of MB encapsulated Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes stored at both 4°C and 25°C for 6 months are given in Figure 1 -3, respectively. Only slight increase was observed in mean particle size, zeta potential and encapsulation efficiency of both formulations stored at 4°C at the end of 3 months (p>0.05). Higher alteration was observed in these parameters of both liposomes stored at 25°C when compared with that of stored at 4°C at the end of 3 months (p<0.05). A significant increase in these parameters was observed for all formulations stored at both 4°C and 25°C for 6 months (p<0.05). On the other hand, Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were observed stable due to mean particle size, zeta potential and MB encapsulation efficiency when stored at 25°C for 1 month. When the effect of phospholipid was compared, no significant difference was obtained between Lipoid S PC containing liposomes and DPPC containing ones stored at the same temperature and time durations (p˃0.05). These results are in agreement with the previous studies. [28] [29] [30] In vitro release of MB encapsulated, nanosized Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were evaluated by dialysis method. 27 Lipoid S PC containing liposomes designated slightly faster release of MB when compared with DPPC containing ones (p ˃ 0.05). As shown in Figure 4 , both formulations were exhibited similar release profiles. A number of studies were found in the literature supporting our data.
31, 32
Discussion Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE liposomes were formulated to combine radionuclide and photosensitizer dye (MB) in one injection to achieve both lymphoscintigraphy by nuclear and NIR imaging and also PDT which can help surgery. All formulations were exhibited nanosize (around 100 nm) significant for long-circulation and passive targeting by PEGylation to obtain "stealth" formulations which is essential for EPR effect in tumor accumulation. 33 Lipoid S PC containing liposomes have smaller particle size than DPPC containing ones (p ˃ 0.05). This may be due to liquid cristaline structure of Lipoid S PC which may easily be reduced by extrusion because of more elasticity than gel state phospholipids. Also, PDI values, which is a significant indicator for the homogenity of particle size distribution in a dispersion, of MB encapsulated, Lipoid S and DPPC containing liposomes were observed very small around approximately 0,1. Surface modification was performed by PEG2000-DSPE coating for all formulations for passive targeting of SLN and surrounding tumor tissue by EPR effect which prevents opsonization by RES cells and increasing blood circulation time. DTPA-PE was synthesized for 99m Tc-radiolabeling of formulations due to its metal chelator properties. DTPA is one of the most commonly used metal chelator agent nowadays for efficiently radiolabel liposomes for imaging. 26, 28, 29 Chelating agent DTPA conjugates to the amino head group with -COOH group and by this way while PE was incorporated with the lipid bilayer of liposomes, Tc-99m was incorporated with DTPA with a high efficiency. 25, 26 Zeta potential exhibits the magnitude of the electrostatic repulsion/attraction between particles. Therefore, it affects stability and shelf-life of formulations and provides detailed information about dispersion, aggregation, or flocculation. The zeta potentials of liposomes are proper (-9 --13 mV) to prevent aggregation. 32 The zeta u n c o r r e c t e d p r o o f potential of Lipoid S PC:PEG2000-PE:Chol:DTPA-PE liposomes was slightly higher when compared with DPPC:PEG2000-PE:Chol:DTPA-PE liposomes (p ˃ 0.05) due to different nature of the phospholipids. MB encapsulation efficiency of DPPC containing liposomes was slightly higher than Lipoid S PC containing ones (p > 005) which is due to gel state of DPPC phospholipid providing less leakage of encapsulated drug through the vesicles. Although, the ability to encapsulate hydrophilic drugs within the liposomal vesicles is very limited (5-10%), 33 both formulations exhibited about 10% encapsulation efficiency. The phosphate content of all liposomes was found very high (around 85-90%) which is very essential for obtaining intact liposome vesicles. The phosphate content loss was observed lesser in DPPC liposomes than Lipoid S PC liposomes, but this difference was not statistically significant (p > 005). This may be due to the gel state phospholipid content of DPPC liposomes which is a saturated synthetic lipid and generally forms stable and intact vesicles. Alterations in mean particle size, zeta potential and MB encapsulation efficiency of Lipoid S PC and DPPC liposomes were evaluated for 6 months of storage at both 4°C and 25°C. Change in these parameters is essential to evaluate physical stability of liposomes, because instability may result in phase seperation. Alteration in zeta potential is also a crutial for physical stability in which any alteration may cause aggregation. Leakage of encapsulated drug is essential for physical stability of liposomes during storage because vesicles should protect encapsulated drug during storage. Only a small amount of increase was observed for each measurement in mean particle size, zeta potential and encapsulation efficiency of both MB encapsulated liposomes stored at 4°C at the end of 3 months (p>0.05). Higher alteration was observed in these parameters of both liposomes stored at 25°C when compared with that of stored at 4°C at the end of 3 months (p<0.05). Lipoid S PC and DPPC liposomes were observed stable when stored at 25°C for 1 month. When the effect of phospholipid amount was compared, no significant difference was evaluated between Lipoid S PC and DPPC containing liposomes stored at the same temperature and time durations (p˃0.05). This may be because of the liquid crystalline state structure of Lipoid S PC and its low phase transition temperature. 33 As a result, leakage of MB from Lipoid S PC liposomes was found to be higher than DPPC liposomes which is compatible with previous studies. [28] [29] [30] In vitro release profiles of liposomes are meaningful for predicting an efficient therapeutic effect. The release of MB is faster from liposomes composed of liquid-crystalline type phospholipids, depending on the distance within the polar head groups of liquid crystalline-type phospholipids, and is also faster than in gel state phospholipids.
31, 32 Liposome formulations containing DPPC as the phospholipid showed slightly better in vitro MB release amounts than Lipoid S PC containing liposomes. However, this difference was not significant. These results were comparable with previously published results.
30, 33

Study Limitations
Further in vitro and vivo imaging and therapy studies are surely needed to perform to obtain more certain decisions which are still continuing. Conclusion Methylene blue encapsulated, nanosized, PEGylated, Tc-99m radiolabeled liposomes were designed as potential formulations to accumulate in SLN due to EPR effect by PEGylation for prolonged blood circulation time and nanosize to obtain imaging and therapy. Methylene blue encapsulated, nanosized, PEGylated, Tc-99m radiolabeled Lipoid S PC:PEG2000-PE:Chol:DTPA-PE and DPPC:PEG2000-PE:Chol:DTPA-PE (60:0,9:39:0,1% molar ratio) liposomes were evaluated as promising multifunctional carriers for SLN imaging, mapping by gamma probe, NIR imaging and therapy by PDT which may help surgery from vesicular particle characteristics (i.e. particle size, EE%, phospholipid amount) release profile and physical stability perspectives. Encapsulation of MB in liposomal formulations may reduce some undesired side effects of MB such as allergic reactions, the volume of distribution by increasing accumulation at the desired site and the dose. The poor penetration of MB through the cell membranes and its slight side effects such as allergic reactions may be decreased by encapsulating in liposomal systems. Further in vitro and vivo imaging and therapy studies are needed to give more certain decisions which are still continuing. This study may lead to design more specific radiocontrast agents for both imaging and therapy of many cancers. 
